Forest Lexapro for panic disorder
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryForest's April 30 submission of Lexapro (escitalopram) for the treatment of panic disorder is the fourth supplement for the antidepressant, which has had one of the strongest launches in history following its Aug. 14, 2002 approval for treatment of depression. The drug gained a maintenance claim Aug. 29, 2002, and an oral solution formulation was cleared in November 2002. An sNDA for generalized anxiety disorder was submitted in November 2002 and a social anxiety disorder filing is slated for "late in the fiscal year." Forest projects that the Celexa follow-on will lead the selective serotonin reuptake inhibitor market by 200
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.